Protein Sciences announced that the FDA has approved Flublok (trivalent recombinant hemagglutinin [rHA] influenza vaccine) for use in adults 18–49 years old. Flublok is the first protein vaccine to be made in a 100% egg-free system without growing influenza viruses.
Flublok is a trivalent composition of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using Protein Sciences’ BEVS (baculovirus expression vector system) technology and expresSF+ cell line. Flublok is highly purified and it contains three times the amount of active ingredient in traditional influenza vaccines with no preservatives (eg, thimerosal), antibiotics, or adjuvants. The vaccine can be made quickly without any of the infectious risk associated with traditional manufacturing.
Flublok is available as a single 0.5mL dose for intramuscular injection. Flublok will be widely available for the 2013-2014 influenza season and is available in limited supply for the current season.
For more information call (888) 855-7871 or visit www.flublok.com